FibroGen, Inc.
General ticker "FGEN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $975.4M (TTM average)
FibroGen, Inc. follows the US Stock Market performance with the rate: 23.5%.
Estimated limits based on current volatility of 2.9%: low 8.18$, high 8.67$
Factors to consider:
- Total employees count: 225 as of 2024
- US accounted for 88.2% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Supply chain disruptions, Geopolitical risks, Regulatory and compliance, Operational and conduct risks, Labor/talent shortage/retention
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [6.13$, 26.62$]
- 2025-12-31 to 2026-12-31 estimated range: [8.86$, 33.46$]
Financial Metrics affecting the FGEN estimates:
- Negative: with PPE of -16.1 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -11.56 <= 0.33
- Negative: Shareholder equity ratio, % of -105.16 <= 18.93
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0.69 <= 0.79
- Positive: Inventory ratio change, % of -28.49 <= -0.75
- Positive: Investing cash flow per share per price, % of 10.56 > -0.66
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term FGEN quotes
Long-term FGEN plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $140.73MM | $46.80MM | $29.62MM |
| Operating Expenses | $441.76MM | $369.52MM | $180.04MM |
| Operating Income | $-301.02MM | $-322.72MM | $-150.42MM |
| Non-Operating Income | $6.16MM | $-0.50MM | $-2.95MM |
| Interest Expense | $1.44MM | $8.10MM | $8.25MM |
| R&D Expense | $296.79MM | $266.47MM | $95.69MM |
| Income(Loss) | $-294.87MM | $-323.22MM | $-153.37MM |
| Taxes | $0.36MM | $-0.25MM | $-0.27MM |
| Other Income(Loss) | $1.57MM | $38.74MM | $105.52MM |
| Profit(Loss)* | $-293.65MM | $-245.49MM | $57.94MM |
| Stockholders Equity | $-21.45MM | $-204.17MM | $-225.60MM |
| Inventory | $40.44MM | $41.56MM | $3.15MM |
| Assets | $610.09MM | $423.53MM | $214.53MM |
| Operating Cash Flow | $-145.93MM | $-315.02MM | $-138.00MM |
| Capital expenditure | $38.74MM | $2.52MM | $0.27MM |
| Investing Cash Flow | $89.12MM | $153.66MM | $125.99MM |
| Financing Cash Flow | $46.78MM | $122.75MM | $-0.26MM |
| Earnings Per Share** | $-3.14 | $-2.52 | $0.58 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.